Stay updated with breaking news from Improves Motor Function. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data from the RESKUE Phase 1/2 clinical trial continues to demonstrate safety and efficacy post-FBX-101 systemic administration in patients recently receiving hematopoietic stem cell transplantation
ATH434 protects brain cells and improves motor function in Parkinsonian disorder Oral presentation at the American Academy of Neurology News provided by Share this article MELBOURNE, Australia , April 21, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company") today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) virtual annual meeting. The AAN conference, held this week, i...